1. South Korea Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Samjin Pharmaceutical Co., Ltd.

Samjin Pharmaceutical Co., Ltd.

KKRX:005500
19,600.00
KRW
-50.00
(-0.25%)
1,861.57EPS
10.12P/E
238.35BMarket Cap
Nov 18Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
15,281.19
16,169.16
17,389.34
19,216.83
19,809.05
21,139.48
19,670.52
19,113.95
20,319.64
21,626.05
22,556.46
24,450.77
25,106.82
24,918.72
Basic EPS, GAAP
627
1,664
2,172
2,423
2,891
2,023
966
2,266
2,308
1,727.82
1,460
3,111
1,963
1,861.57
Free Cash Flow per Basic Share
40.6
1,446.89
811.79
3,271.9
2,270.29
1,776.09
942.74
-547.55
-4,114.41
-1,436.68
-956.5
1,571.24
781.09
2,014.45
Dividend per Share
303.35
400.09
500.08
599.97
704.01
800.17
800.24
799.96
799.73
776.72
817.29
810.39
796.43
- -
Book Value per Share
9,072.84
10,121.49
11,889.88
13,626.96
15,725.44
16,086.08
16,051.13
17,350.19
19,033.68
20,810.66
20,772.27
21,346.05
22,942.01
23,603.72
Tangible Book Value per Share
8,901.63
9,891.01
11,572.79
13,311.97
15,402.71
15,741.72
15,440.02
16,659.59
18,195.46
20,029.18
19,183.19
19,590.09
21,238.6
21,907.17
Basic Weighted Avg Shares
13
12
12
12
12
12
12
12
12
13
13
13
12
12
Sales/Revenue/Turnover
192,007
201,305
216,511
239,313
245,272
260,017
241,926
235,165
250,070
274,032
292,129
308,350
309,134
311,367
Operating Margin (%)
15.67
15.69
16.61
17.57
19.14
22.57
18.56
13.71
13.56
8.46
7.01
10.26
8.66
7.94
Depreciation Expense
5,359
6,104
6,542
6,922
6,634
6,257
6,472
6,490
7,360
9,816
16,613
17,401
19,820
21,183
Net Income, GAAP
7,878
20,717
27,043
30,174
35,796
24,883
11,881
27,879
28,404
21,894
18,908
39,233
24,170
23,261
Effective Tax Rate (%)
72.48
31.3
21.83
22.52
22.97
57.97
45.68
15.08
18.64
13.18
- -
10.1
- -
1.97
Profit Margin (%)
4.1
10.29
12.49
12.61
14.59
9.57
4.91
11.86
11.36
7.99
6.47
12.72
7.82
7.47
Working Capital
60,125
64,525
79,250
99,175
114,065
125,157
119,403
112,925
90,358
52,616
1,630
-25
44,421
46,937
LT Debt
- -
- -
- -
- -
- -
- -
704
7,215
39,988
42,671
4,324
593
28,876
28,287
Total Equity
112,983
126,042
148,063
169,695
193,467
197,904
197,474
213,456
234,168
275,864
265,365
261,655
290,395
298,771
Return on Invested Capital (%)
5.21
13.31
16.36
17.81
18.66
12.05
11.97
12.92
10.7
6.08
- -
7.38
- -
5.9
Return on Capital (%)
5.32
13.55
16.52
17.15
19.09
12.59
5.99
13.27
11.18
7.18
- -
11.37
- -
6.25
Return on Common Equity (%)
6.98
17.33
19.73
18.99
19.71
12.72
6.01
13.57
12.69
8.59
6.99
14.89
8.76
8.35

Capital Structure

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
106,640
91,657
101,596
LT Borrowings
28,500
28,000
28,000
LT Finance Leases
376
327
287
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
13
13
13
Market Capitalization
249,991
227,460
238,346

Working Capital

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
191,576
182,644
192,619
Cash, Cash Equivalents & STI
12,906
8,108
20,876
Accounts Receivable, Net
60,262
50,523
55,732
Inventories
110,827
113,424
106,016
Total Current Liabilities
147,155
142,447
145,682
Payables & Accruals
- -
- -
- -
ST Debt
106,640
91,657
101,596
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
7.21%
6.66%
10.98%
Free Cash Flow
28.9%
48.84%
-51.46%
Net Income, GAAP
11.65%
6.88%
-38.39%
Sales/Revenue/Turnover
3.76%
5.66%
0.25%
Total Cash Common Dividend
- -
- -
-4.05%

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
72,559
70,754
80,547
84,490
308,350
2025
70,859
74,612
83,133
80,530
309,134
2026
68,074
79,630
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
243
1,947
359
556.36
3,111
2025
304
382
557.74
719.55
1,963
2026
110.11
482
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
810.39
2025
- -
- -
- -
- -
796.43
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Kyu Seok Cho
Full Time Employees
819
Sector
Health technology
Industry
Pharmaceuticals: major
Address
121 Wausan Ro Seoul SL South Korea 04054
IPO Date
Jun 18, 1988
Website
samjinpharm.co.kr
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Samjin Pharmaceuticals Co., Ltd. (005500.KS) manufactures, markets, and distributes a broad portfolio of prescription, over-the-counter (OTC), and health supplement products targeting therapeutic areas including antipyretic and analgesic medications; circulatory and anti-inflammatory treatments such as Platless (antiarteriosclerotic agent) and Geworin (NSAIDs); gastrointestinal remedies; herbal tonics and hepatic pharmaceuticals; respiratory and antibiotic drugs; anti-cancer therapies; nootropics like Neuracetam and Nutilin (brain function improver); appetite stimulants such as Trestan; anti-thrombotic agents like Flaris; and additional offerings encompassing active pharmaceutical ingredients (APIs) including clopidogrel bisulfate and rosuvastatin calcium, alongside pipeline candidates such as SJP1902 (anticancer immunotherapy), SJP1801 (dementia and Parkinson's), SJP003 (diabetes), SJP006 (antiviral), SA001 (dry eye and Sjogren syndrome), SJP1804 (macular degeneration), SJP1604 and SJP1602 (cancer), the antiviral Tafrid, and diabetes treatment Pobigle. Founded in 1968 and headquartered in Seoul, South Korea, with manufacturing facilities in Busan, the company primarily serves the domestic Korean market while pursuing global expansion through R&D investments exceeding KRW 300 billion annually since 2022 and compliance with international standards. Recent developments include a joint research agreement with ApitBio in December 2024 to co-develop novel antibody-drug conjugates (ADCs) leveraging proprietary linker-payload technology and tumor-targeting antibodies, following a material transfer agreement; a March 2025 collaboration with Simplex to advance an AI-driven ENPP1 inhibitor for cancer immunotherapy; implementation of a second-generation co-CEO structure with Jo Gyu-seok and Choi Ji-hyun in March 2025 amid record 2024 revenues of KRW 3.083 trillion and operating profit up 54.5% to KRW 316 billion; and ongoing preclinical advancement of lead candidate SJN314 (MRGPRX2 antagonist).